Bio-surgery includes various surgical technologies and techniques that reduce intraoperative and postoperative complications by facilitating hemostasis and tissue sealing, is also used in hard tissue regeneration in orthobiologics. Biosurgical products facilitate hemostasis and tissue sealing in various surgical procedures. They are also used for hard tissue regeneration in orthopedics. Bio-surgical products are usually made from natural, synthetic or semi-synthetic materials that cover the incision and facilitate tissue repair. The growing need for effective management and control of blood loss in various surgical conditions has become an important factor driving the demand for these biosurgical products around the world.
According to study, “Europe Biosurgery Market 2020-2027 by Product, Source Type (Natural, Synthetic), Application (Orthopedic, General, Neurological, Cardiovascular), and Country: Trend Outlook and Growth Opportunity” the key players operating in the Europe Biosurgery market include Baxter International, Inc., Hemostasis LLC, Sanofi S.A., Johnson & Johnson, CryoLife Inc., Becton, Dickinson and Company (C.R. Bard), Stryker Corporation, Integra Lifesciences Holdings Corporation, CSL Limited, Pfizer, Inc., Hemostasis LLC, Betatech Medical, B. Braun Melsungen AG, Medtronic PLC and among others. To strengthen their position in the biosurgery market, key companies are currently focusing on adopting strategies such as product innovations, joint ventures, recent developments, mergers & acquisitions collaborations and partnerships.
Major growth factor of European biosurgery market is the strong focus on research & development that leads to the launch of a variety of new products and different technological advancements in the field. Additionally, increase in number of surgeries owing to changing lifestyles and rise in consumer awareness, serve as boosters for growth of the market. Apart from this, non-acceptance of certain products including human tissue, stringent government regulations and high cost may impact the market.
The Europe biosurgery market growth evaluation constitutes the assessment of Italy, Germany, Spain, France, UK, Russia, and the rest of Europe. The UK country’s market growth is fuelled by increased focus of key players on research & development endeavors, high incidence of cardiovascular conditions & diabetes and growth in technological advancements. The high incidence of diabetes and other chronic diseases is attributed to a sedentary lifestyle prevalent across the country, which leads to wound-related complications during surgery. As a result, the demand for biosurgical products in the UK is growing. Conversely, France country is known for its outstanding healthcare services. Therefore, because of this aspect, the country is one of the main preferences for patients seeking first class medical treatment related to biosurgery. France is likely to expand at a noteworthy growth rate throughout the forecast period. Country’s rapidly growing financial system is expected to create new opportunities over the forecast period. In addition, rheumatoid arthritis has become one of the most common forms of autoimmune chronic arthritis, affecting large numbers of people throughout Italy. In addition, the disease is more common in older women; however, it can affect any age group. Rise in rheumatoid arthritis has increased the demand for biosurgery products in the country’s cities. Hence, all of these factors have the ability to expand the scope and growth of the biosurgery market in Italy over the next several years.
For More Information, click on the link below:-
Ankur Gupta, Head Marketing & Communications